Compare Recursion Pharmaceuticals Inc (RXRX) vs Victoria's Secret & Co (VSXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Victoria's Secret & Co — how do they compare? Recursion Pharmaceuticals Inc trades at $3.25 (market cap $1.86B), while Victoria's Secret & Co trades at $76 (market cap $6.26B). The key difference: Victoria's Secret & Co is far larger — about 3.4× Recursion Pharmaceuticals Inc's market cap, and Victoria's Secret & Co is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | VSXY | |
|---|---|---|
Market Cap | $1.86B | $6.26B |
Sector | Health | Consumer Cyclical |
52-Week High | $6.79 | $99.97 |
52-Week Low | $2.84 | $25.56 |
Enterprise Value | $1.38B | $8.64B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Victoria's Secret (VSXY) trades at $78.47, up 3.85% with strong earnings momentum after beating Q2 2026 estimates. The stock shows bearish technical signals but maintains solid fundamentals with a 45.27% ROE and improving cash flow projections. Recent news highlights PINK brand growth and beauty segment acceleration, though the stock faces near-term pressure from sales concerns despite earnings outperformance.
The outlook remains cautiously optimistic with a $97.33 consensus price target representing 24% upside potential. Key opportunities include sustained PINK growth and margin expansion, while risks involve competitive pressures and execution challenges. Analyst consensus leans bullish with 60% buy ratings, but investors should monitor Q3 2026 results for confirmation of the turnaround trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Victoria's Secret & Co
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →
